TenNor Therapeutics Nets HK$598 Million From Hong Kong IPO Ahead of Debut

MT Newswires Live05:48

TenNor Therapeutics (Suzhou) (HKG:6872) raised HK$598.3 million in net proceeds from its initial public offering in Hong Kong.

The final offer price was set at HK$75.70 per H-share, according to a Thursday after-market filing with the Hong Kong Stock Exchange.

The China-based near-commercial stage biotechnology company offered 8.9 million H-shares in the global offering.

The Hong Kong public offer was 9,015.11 times subscribed, with a final allocation of 828,100 shares, representing 9.35% of the total offering.

The international offering was 9.24 times subscribed, with a final allocation of 8 million shares, or 90.65% of the total offering.

An additional 575,450 shares were issued under the partial exercise of the offer size adjustment option.

Cornerstone investors, including AMR Action Fund, Hua Yuan International, and Orient Asset Management, were allotted a combined 3.1 million shares, representing 34.81% of the global offering, according to the filing.

TenNor Therapeutics is set to debut on the Hong Kong bourse on Friday, May 22.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2637835085?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-22 05:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2637835085","market":"us","top_or_hot":-1,"title":"TenNor Therapeutics Nets HK$598 Million From Hong Kong IPO Ahead of Debut","media":"MT Newswires Live","content":"<html><body><p> TenNor <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (Suzhou) (HKG:6872) raised HK$598.3 million in net proceeds from its initial public offering in Hong Kong.</p><p>The final offer price was set at HK$75.70 per H-share, according to a Thursday after-market filing with the Hong Kong Stock Exchange.</p><p>The China-based near-commercial stage biotechnology company offered 8.9 million H-shares in the global offering.</p><p>The Hong Kong public offer was 9,015.11 times subscribed, with a final allocation of 828,100 shares, representing 9.35% of the total offering.</p><p>The international offering was 9.24 times subscribed, with a final allocation of 8 million shares, or 90.65% of the total offering.</p><p>An additional 575,450 shares were issued under the partial exercise of the offer size adjustment option.</p><p>Cornerstone investors, including AMR Action Fund, Hua Yuan International, and Orient Asset Management, were allotted a combined 3.1 million shares, representing 34.81% of the global offering, according to the filing.</p><p>TenNor Therapeutics is set to debut on the Hong Kong bourse on Friday, May 22.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TenNor Therapeutics Nets HK$598 Million From Hong Kong IPO Ahead of Debut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTenNor Therapeutics Nets HK$598 Million From Hong Kong IPO Ahead of Debut\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-22 05:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> TenNor <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (Suzhou) (HKG:6872) raised HK$598.3 million in net proceeds from its initial public offering in Hong Kong.</p><p>The final offer price was set at HK$75.70 per H-share, according to a Thursday after-market filing with the Hong Kong Stock Exchange.</p><p>The China-based near-commercial stage biotechnology company offered 8.9 million H-shares in the global offering.</p><p>The Hong Kong public offer was 9,015.11 times subscribed, with a final allocation of 828,100 shares, representing 9.35% of the total offering.</p><p>The international offering was 9.24 times subscribed, with a final allocation of 8 million shares, or 90.65% of the total offering.</p><p>An additional 575,450 shares were issued under the partial exercise of the offer size adjustment option.</p><p>Cornerstone investors, including AMR Action Fund, Hua Yuan International, and Orient Asset Management, were allotted a combined 3.1 million shares, representing 34.81% of the global offering, according to the filing.</p><p>TenNor Therapeutics is set to debut on the Hong Kong bourse on Friday, May 22.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SPCX","symbol_name":"SPAC and New Issue ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2637835085","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2637835085","pubTimestamp":1779400136,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"TenNor Therapeutics   raised HK$598.3 million in net proceeds from its initial public offering in Hong Kong.The final offer price was set at HK$75.70 per H-share, according to a Thursday after-market filing with the Hong Kong Stock Exchange.The China-based near-commercial stage biotechnology company offered 8.9 million H-shares in the global offering.The Hong Kong public offer was 9,015.11 times subscribed, with a final allocation of 828,100 shares, representing 9.35% of the total offering.The international offering was 9.24 times subscribed, with a final allocation of 8 million shares, or 90.65% of the total offering.An additional 575,450 shares were issued under the partial exercise of the offer size adjustment option.Cornerstone investors, including AMR Action Fund, Hua Yuan International, and Orient Asset Management, were allotted a combined 3.1 million shares, representing 34.81% of the global offering, according to the filing.TenNor Therapeutics is set to debut on the Hong Kong b","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SPCX":"SPAC and New Issue ETF","LENZ":"Therapeutics","BK4139":"生物科技","IPOS":"Renaissance International IPO ETF","BK4007":"制药","06872":"丹诺医药-B","BK4539":"次新股"},"translate_title":"TenNor Therapeutics在香港IPO上市前净赚5.98亿港元","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPOS":1.5,"SPCX":1.5,"LENZ":1.5,"06872":1},"content_text":"TenNor Therapeutics (Suzhou) (HKG:6872) raised HK$598.3 million in net proceeds from its initial public offering in Hong Kong.The final offer price was set at HK$75.70 per H-share, according to a Thursday after-market filing with the Hong Kong Stock Exchange.The China-based near-commercial stage biotechnology company offered 8.9 million H-shares in the global offering.The Hong Kong public offer was 9,015.11 times subscribed, with a final allocation of 828,100 shares, representing 9.35% of the total offering.The international offering was 9.24 times subscribed, with a final allocation of 8 million shares, or 90.65% of the total offering.An additional 575,450 shares were issued under the partial exercise of the offer size adjustment option.Cornerstone investors, including AMR Action Fund, Hua Yuan International, and Orient Asset Management, were allotted a combined 3.1 million shares, representing 34.81% of the global offering, according to the filing.TenNor Therapeutics is set to debut on the Hong Kong bourse on Friday, May 22.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2637835085","isCrawlerRequest":true}